Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

After divesting its active pharmaceutical ingredient segment, the slimmed-down company will have more time to focus on developing new blockbuster drugs.

Sanofi Spins Off an Industry-Leading Business

SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer

CSL Ltd

Merck

Their coronavirus projects fell behind, faltered, or failed.

3 Coronavirus Stocks to Stay Miles Away From in 2021

Heineken NV

The Invesco European Growth Fund (Trades, Portfolio) disclosed last week that its top five trades during the fiscal fourth quarter included new holdings in Heineken NV (XAMS:HEIA), TGS-NOPEC Geophysical Co. ASA (OSL:TGS) and Sanofi SA (NASDAQ:SNY)(XPAR:SAN). The fund also divested out of Allianz SE (XTER:ALV) and Essilorluxottica (XPAR:EL).

Invesco European Growth Fund's Top 5 Trades of the 4th Quarter

AbbVie

Bristol-Myers

Johnson & Johnson

Novartis

Pfizer

Takeda Pharmaceutical

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence

French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.

Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Biogen

Bank of New York Mellon

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Roche Holding AG

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Cara Therapeutics

Canopy Growth

GrowGeneration Corp

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Stance appeared first on InvestorPlace.

6 Cannabis Stocks to Buy as the U.S. Softens Its Stance

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - November 2020

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

AstraZeneca

Moderna

The challenges for two big drugmakers could translate to opportunities for their rivals in the COVID-19 vaccine race.

Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

Health-care stocks are in focus after Pfizer began shipments in the U.S. of its Covid vaccine and the first vaccinations were given this week.

One health-care stock looks like a buy as Pfizer begins Covid vaccine rollout, market analyst says

Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 

The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.

Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults

Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.

Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate

Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn't work as well in older people. The drugmakers' Friday announcement created a roadblock in its race to produce a safe and effective inoculation for COVID-19 — the same day Health and Human Services Secretary Alex Azar said the.

Sanofi, GlaxoSmithKline delay COVID-19 vaccine rollout to late 2021

Sanofi and GlaxoSmithKline, the French and British pharmaceutical groups, said on Friday that they would delay the launch of their joint coronavirus vaccine until the end of 2021.

Sanofi/GSK vaccine setback adds to uncertainty ahead of Europe's mass inoculation campaigns

The vaccine will not be available until the last quarter of 2021.

Sanofi-GSK Covid-19 Vaccine Delayed After Trials Show Poor Immune Response In Elderly

A COVID-19 vaccine being developed by two of the world's biggest vaccine makers, GlaxoSmithKline and Sanofi, has been delayed after it didn't show a strong enough response in older people. GlaxoSmithKline and Sanofi are now expecting potential distribution of their shot in the final months of 2021. Initially, they had expected the vaccine to be available from mid-2021.

GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.

Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic.

Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) on Friday reported a delay in their COVID-19 vaccine program as interim results from Phase 1 and 2 trials indicate a low immune response in older adults. What Happened: The drugmakers said in a statement that early-stage vaccine trials indicate a low immune response in older adults — most likely caused by an insufficient concentration of the antigen.

GSK-Sanofi COVID-19 Vaccine Shows Insufficient Immunity, Late-Stage Trials Delayed

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

Novavax

There are plenty of catalysts on the horizon for these investments -- and a healthy dose of risk.

News for Sanofi Stock (SNY)